Matinas BioPharma Reports $1.5 Million Net Loss in Q3 2025, Sees Significant Reduction in R&D Expenses

Matinas BioPharma Holdings, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $1.5 million for the three months ended September 30, compared to a loss of $4.3 million during the same period in 2024. For the nine months ending September 30, 2025, the company recorded a net loss of $8.4 million, a significant reduction from the $15.8 million loss reported in the prior year. The decrease in losses is attributed to a substantial reduction in research and development expenses, which fell to $0 for the third quarter and $85,000 for the nine months, down from $2.2 million and $9.1 million, respectively, in 2024. General and administrative expenses also decreased to $1.6 million for the quarter and $5.3 million for the nine months, compared to $2.1 million and $7.1 million in the prior year.

The company’s total assets decreased to $9.7 million as of September 30, 2025, down from $12.6 million at the end of 2024. This decline was primarily driven by a reduction in cash and cash equivalents, which fell to $5.4 million from $7.3 million. Current liabilities also decreased significantly to $1.5 million from $2.7 million, reflecting a reduction in accrued expenses. The company’s stockholders’ equity decreased to $6.5 million from $7.6 million, largely due to the accumulated deficit growing to $208.9 million.

In terms of strategic developments, Matinas BioPharma completed a private placement of 3,300 shares of Series C Convertible Preferred Stock in February 2025, generating gross proceeds of $3.3 million. This funding is intended to support the company’s ongoing operations and development efforts. The company also reclassified its warrants from liability to equity following an amendment to their terms, which is expected to simplify its financial reporting going forward.

Operationally, Matinas BioPharma has paused its development program for MAT2203, which has led to a significant reduction in research and development costs. The company is currently focused on securing partnerships to monetize MAT2203 and is exploring additional strategic options, including potential mergers or licensing agreements. As of September 30, 2025, the company had 5,901,091 shares of common stock outstanding, an increase from 5,086,985 shares at the end of 2024, reflecting ongoing efforts to manage its capital structure.

Looking ahead, Matinas BioPharma anticipates continued operating losses as it seeks to advance its product candidates and secure additional funding. The company has expressed concerns regarding its ability to continue as a going concern, given that its current cash reserves may not be sufficient to fund operations beyond the next twelve months. Management is actively pursuing various financing options, including public and private equity offerings, to support its strategic initiatives and operational needs.